GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » ROA %

CanSino Biologics (HKSE:06185) ROA % : -2.64% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CanSino Biologics's annualized Net Income for the quarter that ended in Jun. 2024 was HK$-238.0 Mil. CanSino Biologics's average Total Assets over the quarter that ended in Jun. 2024 was HK$9,032.7 Mil. Therefore, CanSino Biologics's annualized ROA % for the quarter that ended in Jun. 2024 was -2.64%.

The historical rank and industry rank for CanSino Biologics's ROA % or its related term are showing as below:

HKSE:06185' s ROA % Range Over the Past 10 Years
Min: -16.27   Med: -10.97   Max: 20.8
Current: -10.26

During the past 9 years, CanSino Biologics's highest ROA % was 20.80%. The lowest was -16.27%. And the median was -10.97%.

HKSE:06185's ROA % is ranked worse than
76.55% of 1032 companies
in the Drug Manufacturers industry
Industry Median: 2.25 vs HKSE:06185: -10.26

CanSino Biologics ROA % Historical Data

The historical data trend for CanSino Biologics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics ROA % Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROA %
Get a 7-Day Free Trial Premium Member Only -9.42 20.80 -7.43 -14.10 -4.33

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.83 -21.24 -7.58 -2.64 -

Competitive Comparison of CanSino Biologics's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's ROA % distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's ROA % falls into.


;
;

CanSino Biologics ROA % Calculation

CanSino Biologics's annualized ROA % for the fiscal year that ended in Dec. 2024 is calculated as:

ROA %=Net Income (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=-404.524/( (10192.673+8496.675)/ 2 )
=-404.524/9344.674
=-4.33 %

CanSino Biologics's annualized ROA % for the quarter that ended in Jun. 2024 is calculated as:

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=-238.032/( (9308.183+8757.219)/ 2 )
=-238.032/9032.701
=-2.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2024) net income data. ROA % is displayed in the 30-year financial page.


CanSino Biologics  (HKSE:06185) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-238.032/9032.701
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-238.032 / 736.948)*(736.948 / 9032.701)
=Net Margin %*Asset Turnover
=-32.3 %*0.0816
=-2.64 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


CanSino Biologics ROA % Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Executives
Yu Xuefeng 2501 Other
Chao Shou Bai 2202 Interest of your spouse
Mao Helen Huihua 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Zhu Tao
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics Headlines

No Headlines